These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 17692064)

  • 1. Adalimumab vs. etanercept in psoriasis.
    Downs AM
    Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
    [No Abstract]   [Full Text] [Related]  

  • 2. The return of investment of translational research in inflammatory dermatoses.
    van de Kerkhof PC
    J Dermatolog Treat; 2008; 19(6):317. PubMed ID: 18982511
    [No Abstract]   [Full Text] [Related]  

  • 3. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching biologics for psoriasis.
    Ormerod AD
    Br J Dermatol; 2010 Oct; 163(4):667-9. PubMed ID: 20854399
    [No Abstract]   [Full Text] [Related]  

  • 7. [Biologics in the treatment of psoriasis].
    Dissemond J; Grabbe S
    MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: a case series.
    Bhutani T; Koo J
    J Dermatolog Treat; 2011 Apr; 22(2):75-8. PubMed ID: 20524874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newer treatment options for patients with moderate-to-severe psoriatic disease.
    Roebuck HL
    Nurse Pract; 2006 Aug; 31(8):5-6,11. PubMed ID: 16966969
    [No Abstract]   [Full Text] [Related]  

  • 10. [European and British recommendations on the role of biologic interventions in moderate to severe psoriasis].
    Bachelez H; Battistella M
    Ann Dermatol Venereol; 2011 Apr; 138(2 Suppl 2):H14-7. PubMed ID: 21703457
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-TNF-alpha therapy in childhood pustular psoriasis.
    Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
    Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advertisements for TNF Inhibitors.
    Med Lett Drugs Ther; 2008 Nov; 50(1299):89. PubMed ID: 19008788
    [No Abstract]   [Full Text] [Related]  

  • 14. Experience with biologics for psoriasis in daily practice: switching is worth a try.
    Lecluse LL; de Groot M; Bos JD; Spuls PI
    Br J Dermatol; 2009 Oct; 161(4):948-51. PubMed ID: 19663876
    [No Abstract]   [Full Text] [Related]  

  • 15. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
    Rallis E; Verros CD
    Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
    [No Abstract]   [Full Text] [Related]  

  • 16. A scientific debate: key clinical questions in the management of psoriasis.
    Stingl G
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():1. PubMed ID: 22758910
    [No Abstract]   [Full Text] [Related]  

  • 17. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept.
    Field S; Regan AO; Sheahan K; Collins P
    Clin Exp Dermatol; 2010 Oct; 35(7):795-6. PubMed ID: 20831604
    [No Abstract]   [Full Text] [Related]  

  • 18. Adalimumab treats psoriasis in patients previously treated with etanercept: a case series.
    Yamauchi PS; Mau N
    J Am Acad Dermatol; 2009 Jul; 61(1):158-60. PubMed ID: 19539861
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of necrobiosis lipoidica with etanercept and adalimumab.
    Zhang KS; Quan LT; Hsu S
    Dermatol Online J; 2009 Dec; 15(12):12. PubMed ID: 20040262
    [No Abstract]   [Full Text] [Related]  

  • 20. [What is the impact of the new clinical trial data? What are the lessons for patient management?].
    Passeron T; Boulinguez S
    Ann Dermatol Venereol; 2010 May; 137(5 Suppl 1):11-5. PubMed ID: 20510174
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.